Di seguito l'elenco completo dei nostri comunicati stampa (pagina 5 di 28):
Capricor Therapeutics will discuss the latest FDA regulatory updates for its Duchenne program during a webcast.
Tonix Pharmaceuticals reveals Phase 3 success for TNX-102 SL in fibromyalgia, aims for 2025 FDA approval.
AstraZeneca’s Fasenra recommended in EU for relapsing eosinophilic granulomatosis with polyangiitis, based on Phase III data.
Innate Pharma receives FDA clearance to begin Phase 1 trial of IPH4502, a Nectin-4-targeting ADC for solid tumors.
LEO Pharma gains EC approval for Anzupgo® cream, offering a new treatment for moderate to severe chronic hand eczema.
Datopotamab deruxtecan shows progression-free survival benefits but fails to meet overall survival in key breast cancer trial.
BioAtla and Context Therapeutics sign a deal for BA3362, a TCE antibody for solid tumours, with Context leading development and commercialization efforts.
Chugai wins approval for Evrysdi to treat pre-symptomatic SMA, enabling early intervention for infants through genetic screening.
Japan approves Veltassa® for hyperkalemia treatment in adults, offering effective potassium control for CKD and HF patients.
India's largest-ever analytica Anacon India, India Lab Expo, and Pharma Pro&Pack Expo to bring global insights to Hyderabad.
atalyst Pharmaceuticals' partner, DyDo Pharma, gets approval to commercialize FIRDAPSE® in Japan for LEMS.
Allergan Aesthetics launches 2024 BOTOX® Cosmetic grants, empowering women entrepreneurs through mentorship, grants, and crowdfunding support.
Acurx Pharmaceuticals unveils exciting ibezapolstat research, spotlighting its potential against C. difficile infections.
Takeda gains approval in Japan to market FRUZAQLA for advanced colorectal cancer, providing new hope for patients.
Dr. R.N. Gupta appointed as National President of IPA for 2024-2026. With 50 years in pharma, he has made significant contributions to the industry.
Preclinical data for the treatment of KRAS mutated cancers to be presented at the 6th Annual RAS-Targeted Drug Development Summit.
Alvotech begins a trial for AVT16, a biosimilar to Entyvio®, to test its effectiveness and safety for Ulcerative Colitis.
Cyclacel Pharmaceuticals completes enrollment of 12 patients in Cohort 8 of its Phase 2 study of fadraciclib for advanced solid tumors and lymphoma.
Merck's KEYTRUDA (pembrolizumab) has gained expanded approval in Japan for non-small cell lung cancer and urothelial carcinoma, offering new treatment options.
Sanner's acquisition of Gilero enhances its global CDMO services and capabilities in drug delivery and medtech.
AbbVie’s analysis shows upadacitinib improves moderate-to-severe atopic dermatitis in the head and neck over 16 weeks.
Pfizer voluntarily recalls all OXBRYTA® lots from global markets, addressing concerns for sickle cell disease treatment.
Analytica Anacon, India Lab Expo & Pharma Pro & Pack Expo 2024, Hyderabad, attracts over 25,000 participants exploring innovations in pharma and packaging.
Acurx’s ibezapolstat enhances microbiome health, reduces CDI recurrence, and shows activity against anthrax in trials.
Enanta Pharmaceuticals reports promising Phase 2a results for EDP-323, showing significant RSV viral load reduction and strong safety.
NI Pharmaceuticals unveils FDA-approved Ketoconazole Shampoo, 2%, a generic to Nizoral®, in a $69.2M market.
Merck unveils new long-term data on tulisokibart for UC and CD at UEG Week 2024, showcasing sustained efficacy and safety from Phase 2 studies.
Vertex reveals Phase 3 data on vanza triple CF therapy at NACFC, showing long-term benefits of TRIKAFTA in children.
Acadia’s Board grants equity awards to new CEO Catherine Owen Adams as part of the 2024 Inducement Plan.
Join the 23rd ISoP Annual Meeting in Montreal from October 1–5, 2024, to explore global perspectives on pharmacovigilance and advanced therapeutics.
Tonix Pharmaceuticals secures a U.S. patent for Zembrace® SymTouch® autoinjector, promoting non-oral treatments for faster migraine relief.
New preclinical data on Ketamir-2 will be presented at the 18th Annual Pain Therapeutics Summit in Boston.
Lupin's unit received a Form 483 with three observations, Alembic got an EIR, while Piramal received no observations and an EIR from USFDA.
Jeil Pharmaceutical launches Jaqbo, a P-CAB for peptic ulcers, marking its first in-house drug in 65 years and entering Korea's $1 billion market.
Bayer submits sNDA for NUBEQA to the FDA, aiming to expand its use in metastatic prostate cancer with ADT.
Eris Lifesciences secures CDSCO approval to manufacture an FDC for type 2 diabetes, with Phase IV trials required post-launch.
AbbVie applies for FDA accelerated approval of telisotuzumab vedotin for previously treated non-small cell lung cancer.
Dupixent, by Sanofi and Regeneron, is now FDA-approved for COPD, marking its sixth indication for this blockbuster drug.
Innate Pharma and the Icahn School of Medicine will co-host a hybrid symposium, "Next Generation Immunotherapy Discoveries," on October 3, 2024.
Daewoong Pet enters the CRO sector to develop specialized veterinary medicines, addressing the growing demand for pet pharmaceuticals and clinical trials.
The FDA granted Priority Review for Enhertu, targeting HER2-low breast cancer patients based on positive DESTINY-Breast06 trial results.
Ascendis Pharma submits sBLA to the FDA for TransCon hGH to treat adults with growth hormone deficiency.
Seres Therapeutics sells VOWST™ rights to Nestlé, refocusing on biotherapeutics for high-risk infections in vulnerable patients.
Scorpius Holdings partners with a clinical-stage immuno-oncology firm, offering bioanalytical services and expanding GMP manufacturing capabilities.
Aligos Therapeutics names David Perry as VP of Business Development to drive partnerships and advance its drug pipeline.
BioAtla to showcase Evalstotug (BA3071), a CAB anti-CTLA-4 antibody, at the 2024 Society for Melanoma Research Congress.
Plus Therapeutics presents encouraging safety and efficacy data from Phase 1/2 trial for recurrent glioblastoma therapy.
Surmodics gains FDA approval for the Pounce XL Thrombectomy System, broadening its platform for treating peripheral arteries.
Addition of CN201’s bispecific antibody, enhances Merck's pipeline, targeting B-cell malignancies and autoimmune diseases.
Amneal and Metsera have partnered to develop and supply new global weight loss medicines for obesity and metabolic diseases.
SAWC Fall offers a platform to educate clinicians on the AC5 Advanced Wound System, showcase case studies, and hold strategic meetings with wound care firms.
Recipharm and Exela Pharma Sciences have partnered to enhance sterile manufacturing in the US, focusing on injectable pharmaceutical production.
Pliant Therapeutics appoints Dr. Gary Palmer as Senior VP of Medical Affairs, bringing 25+ years of medical leadership
Brazil honored by WHO for eliminating lymphatic filariasis, a major public health issue. Through strong measures, it joins 19 countries free from the disease.
Scorpius selected for MCDC membership, advancing medical countermeasures to protect against CBRN threats and safeguard national security.
Processa Pharmaceuticals dosed its first patient in a Phase 2 trial for NGC-Cap, aiming to improve breast cancer chemotherapy.
Recursion announced FDA clearance for its IND application to begin a Phase 1/2 trial of REC-1245, targeting biomarker-enriched solid tumors and lymphoma.
Charles River and Lundbeck have partnered to use AI-powered Logica® to enhance the discovery of novel drugs targeting central nervous system disorders.
In 2024, Globus set forth several new system extensions, including the TENSOR™ Suture Button System, & received FDA clearance for orthopaedic products.
Alembic Pharmaceuticals has secured US FDA final approval for its Lamotrigine Extended-Release Tablets in 200 mg, 250 mg, and 300 mg dosages.
Gilead signs licensing deals with six manufacturers to produce generic lenacapavir for HIV prevention in 120 nations.
Afton Scientific Expands Virginia Facility with $200M Investment, creating 200+ Jobs and Boosting Local Biopharma Innovation and Economic Growth.
Lonza acquires Roche's Vacaville biologics site for $1.2 billion, enhancing U.S. manufacturing capacity for next-gen therapies.
Norgine appoints Janneke van der Kamp as CEO, effective January 1, 2025, to drive growth and innovation.
Lilly invests $4.5B in a new Medicine Foundry to boost drug innovation, optimize production, and create 400 jobs in Indiana's LEAP District.
Nicomac Mangini unveils ANIMA AI at CPHI Milan 2024, optimizing pharmaceutical production with real-time monitoring and digital twin simulation.
Kane Biotech gets $75k in NRC IRAP support for DispersinB® Wound Gel R&D, plus $200k for revyve™ tech advancement.
Legend Biotech announces a new R&D facility in Philadelphia, set to boost its next-gen cell therapies by Q3 2025.
David Meline adds deep financial and industry expertise to Lonza’s Board, while Olivier Verscheure has chosen not to stand for re-election at the 2025 AGM.
analytica Anacon India 2024 highlighted 7,000+ products, attracting 25,000 visitors and fostering global innovation.
Charles River Laboratories will showcase 18 scientific posters at Neuroscience 2024, held from October 5-9 in Chicago, collaborating with clients and experts.
Amira Modi joins Sygnature Discovery as COO and Board Member, bringing extensive life sciences experience to drive growth and innovation.
Discover Cellevate's innovative nanofiber microcarriers at CPHI Milan, enhancing viral vector production with 60x more cell growth area.
Sterling Pharma Solutions partners with Soligenix to manufacture GMP-quality synthetic hypericin for clinical development of HyBryte™ targeting rare diseases
WHO established the Global Strategic Plan to tackle diseases like dengue and Aedes -borne arboviruses.
Theriva Biologics presents positive DSMC review for Phase 1b/2a trial of SYN-004 in allogeneic hematopoietic cell transplant recipients, advancing to Cohort 3.
WHO lists first mpox diagnostic under Emergency Use, expanding testing capacity in countries facing outbreaks.
WHO clears single-dose HPV vaccine Cecolin®, expanding vaccine access and helping prevent cervical cancer in girls worldwide
Recordati strengthens its rare diseases portfolio by acquiring Enjaymo®, the only treatment for cold agglutinin disease.
Halozyme collaborates with argenx, adding four new targets for ENHANZE® technology to enhance subcutaneous drug delivery.
Telix’s Illuccix® gains Health Canada approval for selecting mCRPC patients for PSMA-targeted radionuclide therapy.
With 12 fatalities from Marburg, Rwanda initiates a vaccine trial to combat the outbreak and safeguard citizens' health.
AstraZeneca has licensed CSPC's Lp(a) disruptor, YS2302018, aiming to enhance treatments for dyslipidaemia.
DKSH Korea acquires Kyowa Kirin Korea’s specialty pharma unit, enhancing its hematology and nephrology portfolio with key products like Grasin.
Aspire Pharma expands its dermatology and allergy lines by acquiring Canute Pharma, enhancing its portfolio with innovative patient care products.
OnKure merges with Reneo to form OnKure Therapeutics, trading as ‘OKUR,’ advancing cancer treatment innovation.
Discover the 800% surge in mRNA licensing agreements since 2019, highlighting growing confidence in innovative therapies and vaccines.
Afton Scientific expansion in Albemarle County with a $200M investment, adding 200+ jobs and advancing biotech capabilities.
Airsupra significantly reduces the risk of severe asthma attacks, showing positive results in the BATURA Phase IIIb trial.
MTPA shares insights on RADICAVA ORS® treatment for ALS patients at the 2024 NASP Annual Meeting & Expo.
At CPHI Milan 2024, Thermo Fisher will highlight innovations in drug development and sustainability initiatives in healthcare.
Nobel Prize in Medicine honors two Americans for discovering microRNAs, essential in controlling gene expression.
Vincerx Pharma's Phase 1 trial of VIP943 demonstrates positive results in AML, HR-MDS, and B-ALL with complete responses, no dose-limiting toxicities.
Orchard Therapeutics teams up with Er-Kim to distribute Libmeldy, a gene therapy for early-onset MLD in Turkey & Eurasia.
Celly Nutrition partners with FUSION to expand the reach of unbuzzd™, an alcohol metabolism supplement.
Inozyme Pharma adds Erik Harris to its board, leveraging his expertise to advance rare disease therapy INZ-701.
Nipro Launches D2F™ Vials with Stevanato Group's EZ-fill® Technology for Pharma Industry's RTU Needs.
Boehringer Ingelheim's survodutide receives FDA Breakthrough Therapy status for metabolic dysfunction-associated steatohepatitis, accelerating clinical trials.
Synexa Life Sciences boosts its bioanalysis capabilities with the acquisition of Alderley Analytical, enhancing biomarker services for drug development.
Virios Therapeutics and Wex Pharmaceuticals team up to launch Dogwood Therapeutics, advancing treatments for neuropathic pain, fibromyalgia, and Long-COVID.
Discover innovations in battery production, energy storage, and electric mobility at AMPTECH India Expo 2024, Gujarat.
KEYNOTE-689 trial shows KEYTRUDA’s success in improving event-free survival and pathological response in LA-HNSCC.
Positive results from the Phase 3 ASPEN study highlight brensocatib’s potential in treating bronchiectasis effectively.
India has been commended by WHO for eliminating trachoma as a public health problem through effective sanitation efforts.
RTI Surgical has agreed to acquire Collagen Solutions, aiming to boost its capabilities in collagen-based medical devices.
Intas Pharmaceuticals welcomes Sridharan S as Executive VP of API Operations, bringing 28 years of expertise to the role.
Colorcon partners with LOTTE to expand pharma solutions, offering exclusive access to advanced drug formulation and delivery polymers.
Eppendorf launches the CellXpert CS220, a CO2 incubator shaker with 180˚C sterilisation for superior contamination protection and increased flask capacity.
Kindeva Drug Delivery's Bridgeton facility marks a milestone with its first registration batch, boosting injectable fill-finish services and capacity.
BD and ten23 Health Partner to Innovate Aseptic Manufacturing with RFID Technology for Enhanced Prefillable Syringe Traceability.
Tonix Pharmaceuticals partners with X-Chem to harness AI in developing broad-spectrum antiviral drugs, aiming to boost virus-fighting capabilities worldwide.
Novo Nordisk's new global initiative aims to prevent childhood obesity through tailored interventions in six cities.
Cipher Pharmaceuticals names Dr. Hamed Ghanei as CBO, bringing 15+ years of experience in pharmaceuticals and M&A deals.
Catalyst Pharmaceuticals contributes $100,000 to the American Red Cross to aid families destroyed by Hurricane Helene.
Attend the 6th Annual Pharma Manufacturing and Automation Convention in Hyderabad on October 17-18 for industry insights.
Capricor initiates FDA rolling submission for deramiocel to treat DMD cardiomyopathy and seeks full approval by 2024.
Viatris announces successful Phase 3 trial in Japan, showing EFFEXOR®'s efficacy and safety for treating GAD.
Entrada Therapeutics shares positive clinical and preclinical data on DMD treatments at the World Muscle Congress 2024.
Merck will showcase critical findings from its vaccine and infectious disease portfolio at IDWeek 2024, including RSV and HIV research.
Pharma Now celebrates CPHI Milan's 14 awardees for innovation in pharma, from AI-enabled APIs to sustainability, showcasing industry excellence.
Insitro teams up with Eli Lilly to develop AI-driven therapies targeting metabolic diseases, including MASLD.
Mestag collaborates with MSD to discover novel drug targets for inflammatory diseases using its RAFT platform.
Pharma Now recaps CPHI Milan's first two days, highlighting industry innovations, networking, and culinary delights.
Panthera Biopartners becomes the first UK clinical trial site to join Parexel’s global Site Alliance Vaccine Network.
Foghorn's selective SMARCA2 oncology program is part of a U.S. co-development and commercialisation collaboration with Lilly.
Tempest Therapeutics collaborates with Roche to evaluate amezalpat in a Phase 3 trial for unresectable liver cancer.
Cytovale has secured $100 million in funding to accelerate the commercial expansion of IntelliSep for sepsis detection.
Genentech's Itovebi gains FDA approval for PIK3CA-mutated breast cancer, significantly improving treatment outcomes
Nicomac Mangini showcases AI innovations and seismic-certified cleanrooms for optimal pharma production at CPHI 2024.
Pharma Now partners with PharmaPack 2024, covering innovations in pharmaceutical packaging on October 17-18 in California.
Burning Rock and Dizal receive NMPA approval for their co-developed EGFR exon20ins CDx, a first for lung cancer in China.
Arbele collaborates with BioAI and Chime Biologics to accelerate AI-powered cancer therapies and companion diagnostics.
Lipocine's qEEG study confirms CNS engagement of oral brexanolone, supporting its use in psychiatric and neurological conditions.
At IDWeek 2024, GSK and ViiV Healthcare will showcase data on vaccines and treatments for infectious diseases.
Pharma Now celebrates CPHI 2024's success in Milan, featuring groundbreaking pharma innovations, new award categories, and key startups shaping the future.
PW Skills launches School of Healthcare to address India's shortage of trained medical professionals, offering practical and hands-on vocational training.
The second phase of Gaza's polio vaccination campaign starts, aiming to protect 591,700 children with a second dose.
Explore innovations, trends, and regulatory updates in the pharma and chemical industries at Baddi Expo 2024 from Oct 21-23.
The FDA reconsiders the decision, allowing compounders to keep selling cheaper alternatives to Lilly's weight loss and diabetes drugs.
Evonik reorganizes the Coating & Adhesive Resins and Health Care divisions, focusing on core growth areas and divesting non-core businesses for growth.
Enhertu gets conditional approval in China for treating HER2-mutant NSCLC, pending confirmation of clinical benefits.
New data shows Evrysdi helps children with SMA achieve key mobility milestones, underscoring the benefits of early treatment for improved outcomes.
Jonathan Dickinson joins Innate Pharma as CEO and Chairman, bringing extensive biotech expertise to advance innovative immuno-oncology therapies.
LTR Pharma's SPONTAN® shows 470% faster absorption for ED treatment, promising enhanced spontaneity and safety in pivotal study results.
FDA guides Clarity Pharmaceuticals' Phase III trial for 64Cu-SAR-bisPSMA, enhancing prostate cancer diagnostics.
RedHill Biopharma's opaganib selected by BARDA for Ebola treatment, advancing through FDA's Animal Rule with promising results in survival studies.
Samsung Biologics introduces S-HiConTM, a platform enhancing stability and efficacy in high-ose biopharmaceuticals
Ardena secures Catalent's New Jersey facility to boost oral drug manufacturing and broaden its US services.
Exelixis and Merck collaborate to study zanzalintinib with KEYTRUDA and WELIREG in cancer clinical trials.
Lundbeck announces the acquisition of Longboard Pharmaceuticals, which is advancing neurological therapies.
Noul partners with PT Kirana Jaya Lestari to distribute its AI blood testing solution, miLab BCM, in Indonesia, enhancing healthcare efficiency.
Eli Lilly reports promising one-year histologic outcomes for mirikizumab in Crohn's disease, showing significant improvements over ustekinumab.
Cycle Pharmaceuticals proposes to acquire Vanda Pharmaceuticals, offering an 80% premium amid ongoing refusal to engage.
Suven Pharma names Declan Ryan as Chief Commercial Officer. He has 25 years of experience with companies like WuXi, Johnson & Johnson, and Novartis.
Bayer seeks EMA approval for elinzanetant to treat moderate to severe menopause-related hot flashes.
Indaptus progresses Decoy20 Phase 1 trial, with unrestricted patient enrollment at the lower dose approved.
Jazz Pharma Reports Significant Overall Survival and Progression-free Survival for Zezelca and Atezolizumab in First-Line ES-SCLC Maintenance Therapy
Omega Therapeutics announces that it will share preclinical data on epigenomic mRNA medicines at three key conferences.
Pfizer appoints ex-Vanguard CEO Tim Buckley to its Board, joining the Governance, Sustainability, and Audit Committees.
LGM Pharma expands its testing services with endotoxin and rapid sterility testing, offering faster, cost-effective solutions for drug developers.
Pharma India Expo 2024 showcases the latest in pharma machinery, drug development, and networking with industry leaders.
Commit Biologics appoints Dr. Mikkel Pedersen as CSO to lead R&D and develop its BiCE™ technology for cancer and autoimmune therapies.
Berry Global's ClariPPil™ bottles provide sustainable, recyclable packaging with enhanced product protection and reduced CO₂ emissions.
FDA accepts UroGen's NDA for UGN-102, a potential breakthrough for non-muscle invasive bladder cancer, with a PDUFA date of June 2025.
Lantern Pharma's LP-184 secures FDA Fast Track Status, advancing treatment options for Glioblastoma and offering hope for patients.
Circle Pharma's CID-078 enters Phase 1 trials, offering innovative oral treatment options for advanced solid tumors.
LEO Pharma launches Anzupgo® cream in Germany, offering a new treatment for moderate to severe Chronic Hand Eczema.
Astria's navenibart granted OMPD in Europe for HAE, showing 90-96% attack reduction in early trials.
Theriva's VCN-01 receives EU orphan status for retinoblastoma, marking progress in pediatric cancer therapy.
Perspective Therapeutics ships its first patient doses from a new NJ facility, marking a milestone in producing radiopharmaceuticals for cancer treatment.
Keros Therapeutics announces Dr. Yung H. Chyung as Chief Medical Officer, effective November 1, 2024.
Apellis Pharmaceuticals reveals an oral presentation on pegcetacoplan at ASN Kidney Week and two additional posters.
Medical Affairs Summit 2024 in Boston will spotlight strategic innovations, best practices, and regulatory insights in healthcare.
Univercells debuts scale-X™ nexo bioreactor for efficient, scalable cell culture, reducing costs by up to 60%.
Olivier Falut joins EUROAPI as CFO on October 17, 2024, bringing 30 years of financial expertise to the role.
Uhlmann Pac-Systeme inaugurates its new Pune office, showcasing cultural performances and a commitment to innovation.
Tonix Pharmaceuticals submits NDA for TNX-102 SL, which shows efficacy in fibromyalgia in Phase 3 trials and is now under FDA review.
Health Canada approves Acadia’s DAYBUE™ as Canada’s first treatment for Rett syndrome, offering new hope for patients and families.
Matica Bio partners with Mongoose Bio to advance lentivirus production for TCR-T cell therapy, boosting innovation in Texas's biocluster.
Cellular Origins & Fresenius Kabi partner to scale CGT automation, integrating Cue® with Constellation™ for efficient cell therapy production.
AbbVie's VYALEV receives FDA approval as the first 24-hour levodopa-based subcutaneous infusion for advanced Parkinson's.
Kane Biotech signs a 5-year deal to distribute XSONX's Wound Hygiene System across Canada, Australia, and GCC.
Swissmedic grants marketing approval of FILSPARI® for IgAN treatment based on significant phase-III PROTECT trial results from CSL Vifor and Travere.
Charles River introduces the Retrogenix® Non-Human Protein Library to improve off-target assessments.
Orano inaugurates its first 4.0 plant in Cherbourg, producing the TN Eagle cask for safer, efficient nuclear fuel storage.
Virica and eXmoor collaborate, funded by Canada-UK program, to enhance AAV production and reduce gene therapy costs.
Amylyx's AMX0035 shows promising Phase 2 results, improving pancreatic function in Wolfram syndrome patients.
Poseida selects a new CAR-T candidate with Roche, targeting hematologic cancers to enhance treatment options.
Sanofi and Orano Med partner to advance next-gen targeted alpha therapies for rare cancers, combining biopharma and nuclear expertise for precision treatment.
Merck's Clesrovimab cuts RSV risk in infants by 60% in trials, showing promise in preventing severe cases during their first RSV season.
Novo Nordisk's Alhemo® may soon offer the first once-daily subcutaneous treatment for haemophilia A or B with inhibitors.
World Drug Safety Congress 2024 in Boston highlights AI integration, regulatory updates, and innovations in drug safety.
Eylea 8 mg offers extended dosing intervals up to 20 weeks, reducing treatment burden and enhancing patient outcomes.
Korea BNC partners with Dongkook Pharmaceutical to distribute Bienox, a botulinum toxin that reduces frown lines.
FibroBiologics collaborates with Charles River to manufacture fibroblast-based CYWC628 for diabetic foot ulcer trials.
BOTOX® Cosmetic has gained FDA approval for treating platysma bands, becoming the first product in four aesthetic areas.
Dharmesh Kharwar appointed Independent Director at ENTOD Pharmaceuticals, bringing vast industry expertise.
Gland Pharma names Shyamakant Giri as CEO, effective January 2025, bringing over 25 years of global pharma experience.
Omnipaque is approved in Korea for contrast-enhanced mammography, boosting breast cancer detection and patient outcomes.
FDA approves Astellas' gastric cancer treatment, Vyloy, enhancing survival rates alongside chemotherapy.